SUSPECT ADVERSE REACTION REPORT

NI-TOLMAR, INC.-25NI057621

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE	3. SEX	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year	Years		Day	Month	Year	
AGSA	NICARAGUA	01	Dec	2020	4	Female	10	Mar	2025	

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) discharge a small amount of yellow mucous vaginal secretion (Vaginal discharge (10046901), Vaginal discharge (10046901))
(10/Mar/2025 - 10/Mar/2025) - Recovered/Resolved
2) Thick, yellowish discharge from the vagina (Vaginal discharge (10046901), Vaginal discharge (10046901))
(26/Jul/2025 - 26/Jul/2025) - Recovered/Resolved

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☐ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (22.5 Milligram, Injection)(Unknown)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)

1) (22.5 milligram(s), 1 in 3 Month)

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Central Precocious Puberty [10073186 - Central precocious puberty]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (28/Jan/2025 - Ongoing)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) CENTRAL PRECOCIOUS PUBERTY (10073186, Central precocious puberty) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1--9702124900

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED ☐ YES ☐ NO

24b. MFR CONTROL NO.

NI-TOLMAR, INC.-25NI057621

24c. DATE RECEIVED BY MANUFACTURER

28/Jul/2025

24d. REPORT SOURCE ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL

DATE OF THIS REPORT

02/Aug/2025

25a. REPORT TYPE ☐ INITIAL ☑ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This Study report from NICARAGUA was received by Adium via Patient Support Program (reference number: NI-ADIUM-NI-0032-20250312) on 12-MAR-2025 from a Consumer/Other Non-Health Prof regarding child 4 years old female patient who experienced discharge of a small amount of yellow mucous vaginal secretion (Vaginal discharge) during Eligard (Leuprolide acetate) 22.5 milligram therapy for central precocious puberty. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 14-MAR-2025.

The patient's medical history and current conditions included precocious puberty.

Concomitant medications were not reported.

On 28-JAN-2025, the patient began receiving Eligard 22.5 milligram, q 3 month via subcutaneous use for central precocious puberty (Lot number and Expiration date: not reported). On 10-MAR-2025, 1 month 11 days after the most recent dose of Eligard, the patient experienced discharge of a small amount of yellow mucous vaginal secretion, which only occurred on that day. Corrective treatment was not reported. Action taken with Eligard in response to the event was dose not changed. De-challenge and re-challenge were not applicable. The outcome of vaginal discharge was recovered/ resolved.

The reporter did not assess the seriousness or causality of the event in relationship to Eligard.

On 28-Jul-2025, follow up information was received by Adium via Patient Support Program (reference number: NI-ADIUM-NI-0032-20250312 (1)) from a consumer (Non-Health Professional) and sent to Tolmar on 29-Jul-2025. New information included: added a new episode of non-serious event of "Thick, yellowish discharge from the vagina" (Vaginal discharge).

On 26-Jul-2025, the patient experienced thick, yellowish discharge from the vagina. No further information was reported.

Corrective treatment was not reported.

Action taken with Eligard in response to the event was dose not changed. De-challenge and re-challenge were not applicable.

On 26-Jul-2025, the outcome of vaginal discharge was recovered.

The reporter did not assess the seriousness of vaginal discharge.

The reporter assessed the causality of vaginal discharge in relationship to Eligard and Eligard unspecified device as related.

No further query was raised.

Listedness:
vaginal discharge>Eligard>Unlisted as per CCDS>07-Nov-2024
vaginal discharge>Eligard>Unlisted as per USPI>Feb-2025
vaginal discharge>Eligard unspecified device>Unlisted as per USPI>Feb-2025
vaginal discharge>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Listedness of event vaginal discharge was retained as per previous assessment.

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): Causality
vaginal discharge -Not related to drug and device

FU- This is regarding 04-year female child patient who had Vaginal discharge ("Thick, yellowish discharge from the vagina"), during Eligard (leuprolide acetate) 22.5 mg therapy for precocious puberty. Event Vaginal discharge ("Thick, yellowish discharge from the vagina") was added. Tolmar assessed the event as non-serious since it does not meet the ICH seriousness criteria and is not an IME event. The reported event Vaginal discharge was assessed as not related to Eligard (drug and device) considering inconsistence with known safety profile and underlying precocious puberty could better explain the event. Causality and seriousness of vaginal discharge was retained as per previous assessment.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug	: Eligard® (Leuprolide acetate)
Active Substance	: 1) Leuprolide acetate
Drug Characterization	: Suspect
Form Strength	: 1) 22.5 Milligram

Continuation Sheet for CIOMS report

Form of Admin	:	1) Injection
Lot Number	:	1) Unknown
Daily Dose	:	(22.5 milligram(s), 1 in 3 Month)
Route of Admin	:	1) Subcutaneous
Indications	:	1) Central Precocious Puberty [10073186 - Central precocious puberty]
Therapy Dates	:	1) From : 28/Jan/2025 To :Continuing
Action(s) Taken With Drug	:	Dose not changed

Causality

1) discharge a small amount of yellow mucous vaginal secretion (Vaginal discharge - 10046901, Vaginal discharge - 10046901)

Causality as per reporter	:	Not Reported
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

2) Thick, yellowish discharge from the vagina (Vaginal discharge - 10046901, Vaginal discharge - 10046901)

Causality as per reporter	:	Related
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

Labeling :

1) discharge a small amount of yellow mucous vaginal secretion
CORE UnLabeled
2) Thick, yellowish discharge from the vagina
CORE UnLabeled

2) Drug	:	Eligard® Unspecified Device (Leuprolide acetate)
Active Substance	:	1) Leuprolide acetate
Drug Characterization	:	Suspect
Form of Admin	:	1) Injection
Lot Number	:	1) Unknown
Indications	:	1) Central Precocious Puberty [10073186 - Central precocious puberty]
Action(s) Taken With Drug	:	Not applicable

Causality

1) discharge a small amount of yellow mucous vaginal secretion (Vaginal discharge - 10046901, Vaginal discharge - 10046901)

Causality as per reporter	:	Not Reported
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

2) Thick, yellowish discharge from the vagina (Vaginal discharge - 10046901, Vaginal discharge - 10046901)

Causality as per reporter	:	Related
Causality as per Mfr	:	Not Related
DeChallenge	:	Not applicable
ReChallenge	:	Not Applicable

Labeling :

1) discharge a small amount of yellow mucous vaginal secretion
CORE
2) Thick, yellowish discharge from the vagina
CORE

15. DAILY DOSE(S) (Continuation...)

Dosage Text :

Drug 1 :Eligard®

1) 22.5 milligram, q 3 month

Drug 2 :Eligard® Unspecified Device

1) UNK